S11 Ep8: Salgia Summarizes the Benefits of Tepotinib in MET Exon 14–Mutated NSCLC
Dr Salgia discusses how he chooses between tepotinib and capmatinib in patients with stage IV NSCLC harboring MET exon 14 skipping mutations.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.